Flavio Vincenti

MD

Kidney and pancreas transplant specialist

About me

Dr. Flavio Vincenti is a specialist in kidney and pancreas transplantation. He came to UCSF Medical Center in 1975 for a fellowship in transplant nephrology and was appointed a member of the kidney transplant team.

In 1978, Vincenti co-authored an article in the New England Journal of Medicine on the role of blood transfusions in improving kidney transplants. He also wrote a series of articles on the complications of transplants and has been a leading investigator and writer on the use of anti–interleukin 2 receptor monoclonal antibodies, used to reduce the chance of organ rejection. In addition, he is a proponent of minimizing immunosuppressive drugs after transplants.

Vincenti is a member of many professional organizations, including the Transplantation Society, American Society of Nephrology, American Society of Transplantation and International Society of Nephrology. He is a co-leader of the Immune Tolerance Network's kidney section. In addition, he is on the editorial boards of Graft and the American Journal of Kidney Diseases.

  • Education

    American University Medical Center of Beirut, 1971

  • Residencies

    American University Medical Center of Beirut, Internal Medicine

  • Fellowships

    Emory University Hospital, Nephrology, 1975

  • Board Certifications

    Internal Medicine, American Board of Internal Medicine

    Nephrology, American Board of Internal Medicine

  • Academic Title

    Professor

  • Languages

    Arabic

    French

    Italian

Kidney Transplant Center

400 Parnassus Ave., Seventh Floor
San Francisco, CA 94143

Pancreas Transplant Services

400 Parnassus Ave., Seventh Floor
San Francisco, CA 94143

Decorative Caduceus

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an An...

Integrative score that will provide a prediction of graft survival at year 5

Recruiting

Decorative Caduceus

Treg Modulation With CD28 and IL-6 Receptor Antagonists

Definitions: Acute T cell Mediated Rejection: Biopsy proven rejection defined by histologic evidence of a Banff grade of ≥1A and clinical treatment for acute rejection. Acute Antibody Mediated Rejection: Diffusely positive immunos...

Recruiting

Decorative Caduceus

Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants

Achievement of the required duration of persistent donor mixed chimerism to permit calcineurin inhibitor immunosuppressive withdrawal beginning at 6-7 months post-kidney transplant surgery, and Successful withdrawal from all immun...

Recruiting

Decorative Caduceus

Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney

The severity of DGF will be assessed by its duration as measured by the number of days a patient remains dialysis dependent.

Recruiting

Decorative Caduceus

A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients

For pre-transplant when study is administered: Evaluate the incidence of adverse events including clinical laboratory test variables (Complete Blood Count with differential, liver function tests, renal function tests) from the tim...

Recruiting

Decorative Caduceus

Treg Therapy in Subclinical Inflammation in Kidney Transplantation

The safety of polyTregs will be described in comparison with CNI-based maintenance IS therapy.

Recruiting

Decorative Caduceus

Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant ...

Percentage of participants with adjudicated CMV disease through 52 weeks post-transplant

Recruiting

Share